70832-64-3

Usage

Uses

Used in Pharmaceutical Industry:
(5-acetyloxy-3,4-dibenzoyloxy-oxolan-2-yl)methyl benzoate is used as an active pharmaceutical ingredient for its potential therapeutic effects. Its unique molecular structure allows it to interact with biological targets, making it a promising candidate for the development of new drugs.
Used in Cosmetics Industry:
In the cosmetics industry, (5-acetyloxy-3,4-dibenzoyloxy-oxolan-2-yl)methyl benzoate is used as a key ingredient in various formulations. Its properties may contribute to the efficacy, stability, and sensory characteristics of cosmetic products, enhancing their performance and consumer appeal.
Used in Chemical Regulation and Safety:
Due to its presence in various products and potential impact on human and environmental health, (5-acetyloxy-3,4-dibenzoyloxy-oxolan-2-yl)methyl benzoate is a subject of interest in the field of chemical regulation and safety. Its complex structure and potential effects on health and the environment necessitate thorough evaluation and monitoring to ensure safe use and minimize potential risks.

Upstream product

• 108-24-7 acetic anhydride 
• 171866-28-7 1-O-methyl-2,3,5-tri-O-benzoyl-L-ribofuranose 
• 87-72-9 L-xylopyranose 
• 41546-21-8 L-ribose 
• 162491-62-5 (2S,3R,4S)-2-(hydroxymethyl)-5-methoxyoxolane-3,4-diol 
• 55726-00-6 (3R,4S,5R)-5-((trityloxy)methyl)tetrahydrofuran-2,3,4-triol 
• 7296-55-1 L-arabinose 
• 7473-38-3 benzyl β-L-arabinopyranoside 
• 18403-22-0 (3aS,6S,7R,7aR)-6-Benzyloxy-2,2-dimethyl-tetrahydro-[1,3]dioxolo[4,5-c]pyran-7-ol 
• 24259-59-4 L-ribose 
• 98-88-4 benzoyl chloride 
• 1173695-22-1 1-O-acetyl-2,3,5-tri-O-benzoyl-α-L-ribofuranose 
• 6974-32-9 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose 
• 95622-16-5 5-O-trityl-D-ribitol 

Downstream Products

• 91703-94-5 9-(2,3,5-tri-O-benzoyl-β-L-ribofuranosyl)-N-palmitoylguanosine 
• 109923-74-2 2',3',5'-tri-Obenzoyl-L-cytidine 
• 192133-14-5 C₃₂H₂₆O₇Se 
• 179112-78-8 4-N-acetyl-2',3',5'-tri-O-benzoyl-β-L-cytidine 
• 1748-04-5 (2S,3S,4S,5S)-2-((benzoyloxy)methyl)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3,4-diyl dibenzoate 
• 109923-78-6 6-N-benzoyl-2',3',5'-tri-O-benzoyl-β-L-adenosine 
• 237060-98-9 2',3',5'-tri-O-benzoyl-5-methyl-L-uridine 
• 206269-45-6 1-(2,3,5-tri-O-benzoyl-β-L-ribofuranosyl)-5-azacytosine 
• 862543-11-1 9-(2',3',5'-tri-O-benzoyl-β-L-ribofuranosyl)-2-chloro-6-(4-piperonylpiperazin-1-yl)purine 
• 862543-12-2 9-(2',3',5'-tri-O-benzoyl-β-L-ribofuranosyl)-2-piperidino-6-(4-phenylpiperazin-1-yl)purine 
• 952429-09-3 4,5-dichloro-7-(2,3,5-tri-O-benzoyl-β-L-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 
• 952429-12-8 5-bromo-4-chloro-7-(2,3,5-tri-O-benzoyl-β-L-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 
• 952429-13-9 4-chloro-5-iodo-7-(2,3,5-tri-O-benzoyl-β-L-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 
• 952429-10-6 4-chloro-5-fluoro-7-(2,3,5-tri-O-benzoyl-β-L-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 

Relevant academic research and scientific papers

L-nucleoside compounds and application thereof

The invention discloses L-nucleoside compounds having the structure characteristic represented by the formula (I) or pharmaceutically acceptable salts thereof, and belongs to the technical field of pharmaceutical chemistry. The compounds can inhibit the activity of RNA viral polymerase, so the compounds can be used as potential drugs for prevention and treatment of infection of RNA viruses such as HCV, influenza virus, HRV (rhinovirus), RSV, Ebola virus, dengue virus, intestinal virus and the like.

Synthesis of 6-(het) ary Xylocydine analogues and evaluating their inhibitory activities of CDK1 and CDK2 in vitro

A series of purine nucleoside analogues bearing an aryl and hetaryl group in position 6 were prepared and their biological activities were assessed by in vitro CDK1/Cyclin B1 and CDK2/Cyclin A2 kinase assay. From the synthesized chemicals, three Xylocydine derivatives 3h, 3i, and 3j exhibited specific inhibitory activities on CDK2/Cyclin A2 with IC50 values of 4.6, 4.8, and 55 μM, respectively. Those three compounds all induced G1/S phase arrest in Human epithelial carcinoma cell line (HeLa), and the results suggested they may inhibit CDK2 activity in vitro. Furthermore, molecular modeling study, their docking into Cyclin Dependant Kinase 2 (CDK2) active site showed high docking scores. Taken together, these data suggest that, those three compounds are good inhibitors of CDK2 for studying this kinase signal transduction pathway in cell system.

Reaction kinetics and mechanism of acid-catalyzed anomerization of 1-O-acetyl-2,3,5-tri-O-benzoyl-l-ribofuranose

The mechanism of the acid-catalyzed anomerization of 1-O-acetyl-2,3,5-O-benzoyl-α- and -β-l-ribofuranoses in different acetic acid-acetic anhydride mixtures was investigated. The progress of the reactions was followed by NMR spectroscopy and the rate cons

Reaction kinetics and mechanism of sulfuric acid-catalyzed acetolysis of acylated methyl l-ribofuranosides

The mechanism of the sulfuric acid-catalyzed acetolysis of methyl 2,3,5-tri-O-acetyl- and methyl 2,3,5-tri-O-benzoyl-Lribofuranosides and the accompanying anomerization of both the starting material and the 1,2,3,5-tetra-O-acetyl- and 1-O-acetyl-2,3,5-tri-O-benzoyl-L-ribofuranoses formed was investigated. The progress of the reactions was followed by 1H NMR spectroscopy and the rate constants for the reactions were determined for a proposed kinetic model. The role of H+ and Ac + as the catalytically active species was clarified, proving that the anomerization of the acylated methyl furanosides is activated by protonation, while, on the contrary, the anomerization of the 1-O-acetyl ribofuranoses is activated by the acetyl cation. The anomerization of the acylated methyl furanosides was verified to be activated on the ring oxygen leading to endocyclic CO-bond rupture while the 1O-acetyl ribofuranoses are activated on the acetyloxy group on C(1) leading to exocyclic cleavage.

METHOD FOR PRODUCTION OF FURANOSE DERIVATIVE

An object of the present invention is to provide a industrially appropriate method for producing the β-anomers of ribofuranose derivatives in a highly selective manner at a high yield. The present invention provides a method for producing ribofuranose derivatives wherein β-anomers is precipitated from among the generated furanose derivatives by controlling the amount of a reaction reagent used and/or using a poor solvent in the acetolysis reactions of 2,3,5-tri-O-acyl-1-O-alkyl-ribofuranose and 2,3-di-O-acyl-1-O-alkyl-5-deoxy-ribofuranose.

A solid-phase approach to novel purine and nucleoside analogs

This paper describes a method for the preparation of purine analogs using the solid-phase approach. Nucleoside bases were constructed on Merrifield resin by sequential displacement of purine dichloride with amines, and after detachment, the purine analogs were condensed with d,l-ribofuranoside compounds by the Vorbrueggen method. Thereof, l-ribofuranoside was prepared from l-arabinose via the selective oxidation-reduction procedure of the 2-OH group. Some compounds exhibited moderate activity against HIV-1 in PBM cells.

2'-deoxy-L-nucleosides

This invention provides processes for the preparation of compounds having the structure: wherein X and Y are same or different, and H, OH, OR, SH, SR, NH2, NHR′, or NR′R″Z is H, F, Cl, Br, I, CN, or NH2. R is hydrogen, halogen, lower alkyl of C1-C6 or aralkyl, NO2, NH2, NHR′, NR′R″, OH, OR, SH, SR, CN, CONH2, CSNH2, CO2H, CO2R′, CH2CO2H, CH2CO2R′, CH═CHR, CH2CH═CHR, or C═CR. R′ and R″ are same or different, and lower alkyl of C1-C6. R13 is hydrogen, alkyl, acyl, phosphate (monophosphate, diphosphate, triphosphate, or stabilized phosphate) or silyl; and

Methods of treating hepatitis delta virus infection with beta-l-2'-deoxy-nucleosides

A method and composition for treating a host infected with hepatitis D comprising administering an effective hepatitis D treatment amount of a described 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof.

PROCESS FOR THE PREPARATION OF 2'- FLUORO-5-METHYL-BETA-L-ARABINO- FURANOSYLURIDINE

The present invention relates to a novel and improved process for preparing 2′-fluoro-5-methyl-β-L-arabinofuranosyluridine represented by formula (1) which shows anti-viral activity, especially potent anti-viral activity against hepatitis B-virus and Epstein-Barr virus:

β-L-2'-deoxy-nucleosides for the treatment of hepatitis B

This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2''-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2''-deoxy-β-L-erythro-pentofuranonucleoside has the formula: STR1wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2''-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2''-deoxy-β-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.